AUTHOR=Falkenstetter Sarah , Leitner Julia , Brunner Susanne M. , Rieder Tim N. , Kofler Barbara , Weis Serge 

TITLE=Galanin System in Human Glioma and Pituitary Adenoma

JOURNAL=Frontiers in Endocrinology

VOLUME=11

YEAR=2020

URL=https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2020.00155

DOI=10.3389/fendo.2020.00155

ISSN=1664-2392

ABSTRACT=<p>Expression of neuropeptides and their corresponding receptors has been demonstrated in different cancer types, where they can play a role in tumor cell growth, invasion, and migration. Human galanin (GAL) is a 30-amino-acid regulatory neuropeptide which acts through three G protein-coupled receptors, GAL<sub>1</sub>-R, GAL<sub>2</sub>-R, and GAL<sub>3</sub>-R that differ in their signal transduction pathways. GAL and galanin receptors (GALRs) are expressed by different tumors, and direct involvement of GAL in tumorigenesis has been shown. Despite its strong expression in the central nervous system (CNS), the role of GAL in CNS tumors has not been extensively studied. To date, GAL peptide expression, GAL receptor binding and mRNA expression have been reported in glioma, meningioma, and pituitary adenoma. However, data on the cellular distribution of GALRs are sparse. The aim of the present study was to examine the expression of GAL and GALRs in different brain tumors by immunohistochemistry. Anterior pituitary gland (<italic>n</italic> = 7), pituitary adenoma (<italic>n</italic> = 9) and glioma of different WHO grades I–IV (<italic>n</italic> = 55) were analyzed for the expression of GAL and the three GALRs with antibodies recently extensively validated for specificity. While high focal GAL immunoreactivity was detected in up to 40% of cells in the anterior pituitary gland samples, only one pituitary adenoma showed focal GAL expression, at a low level. In the anterior pituitary, GAL<sub>1</sub>-R and GAL<sub>3</sub>-R protein expression was observed in up to 15% of cells, whereas receptor expression was not detected in pituitary adenoma. In glioma, diffuse and focal GAL staining was noticed in the majority of cases. GAL<sub>1</sub>-R was observed in eight out of nine glioma subtypes. GAL<sub>2</sub>-R immunoreactivity was not detected in glioma and pituitary adenoma, while GAL<sub>3</sub>-R expression was significantly associated to high-grade glioma (WHO grade IV). Most interestingly, expression of GAL and GALRs was observed in tumor-infiltrating immune cells, including neutrophils and glioma-associated macrophages/microglia. The presence of GALRs on tumor-associated immune cells, especially macrophages, indicates that GAL signaling contributes to homeostasis of the tumor microenvironment. Thus, our data indicate that GAL signaling in tumor-supportive myeloid cells could be a novel therapeutic target.</p>